Recombinant CD۱۳۷-Fc, applications for modulationinflammation induced by some bacteria and viruses, such as novelcoronavirus.

Background and Aim : CD۱۳۷ (ILA/۴‐۱BB), a member of tumor necrosis factor receptorsuperfamily, is one of the most important T cell costimulatory molecules. Interaction of thismolecule with its ligand transmits a two‐way signal that activates both T lymphocyte and antigenpresenting cells. The soluble form of CD۱۳۷ (sCD۱۳۷) reduces the activity of its membraneisoform and is associated with T lymphocyte activation induced cell death. Recombinant CD۱۳۷‐Fc may be used to treat Infections caused by some microbes including Listeria monocytogenesand novel coronavirus.Methods : The ۱۲۷۶ bp DNA sequence encoded CD۱۳۷‐Fc recombinant protein was prepared andsubcloned into lentiviral vector and expressed in transduced CHO‐K۱ eukaryotic cells. Westernblot analysis, and enzyme‐linked immuno sorbent assay tests were performed. The IL-۶ and IL-۸levels as inflammatory cytokines were measured using the ELISA kitsResults : Different assays results demonstrated that the expression of the ۷۰‐kDa CD۱۳۷‐Fcmolecule was detectable without any degradation. IL-۶ and IL-۸ were significantly decreased inthe sample exposed to soluble CD۱۳۷-Fc protein. While in the samples that were exposed to themembrane CD۱۳۷, there was a significant increase in IL-۸.Conclusion : This study helps to confirm previous research suggesting the use of this recombinantprotein as a promising solution for the treatment of some infections. This product is widely usedin novel medical treatments, including cell‐based immunotherapy such as dendritic cells, CAR T,and CAR NK therapy. This product can be effective in the treatment of Listeria monocytogenesinfections Because of its effect on increasing the activity of neutrophils in the region, also is usefulin the treatment of the ۲۰۱۹ coronavirus disease pandemic Because of its effect on reducingcytokine-induced inflammation.